Afimmune's Epeleuton shows large decreases in viral load and

Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Afimmune, a clinical stage drug discovery company focused on the development

Related Keywords

United States , Ireland , Dublin , American , Kostenloser Wertpapierhandel , Mike Sinclair , Journal Of The American Heart Association , John Climax , Business Wire , American Heart Association , Afimmune , Peleuton , Shows , Barge , Decreases , Viral , Road , Pathological , Changes , Covid , Study ,